HC Wainwright Has Positive Estimate for IN8bio Q2 Earnings

IN8bio, Inc. (NASDAQ:INAB) – Analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for shares of IN8bio in a research report issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.61) per share for the quarter, up from their previous forecast of ($0.68). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for IN8bio’s Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.10) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at ($0.44) EPS, FY2029 earnings at $0.27 EPS and FY2030 earnings at $0.69 EPS.

INAB has been the topic of a number of other reports. Zacks Research raised shares of IN8bio to a “hold” rating in a report on Thursday, January 15th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $4.00.

IN8bio Stock Down 1.5%

NASDAQ:INAB opened at $1.60 on Wednesday. IN8bio has a 52-week low of $1.17 and a 52-week high of $5.61. The stock’s 50 day moving average price is $1.59 and its 200 day moving average price is $1.80. The company has a market capitalization of $15.76 million, a PE ratio of -0.61 and a beta of 0.08.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.33.

Institutional Investors Weigh In On IN8bio

A number of institutional investors have recently added to or reduced their stakes in the business. 683 Capital Management LLC acquired a new position in IN8bio during the 4th quarter worth approximately $1,696,000. Captrust Financial Advisors purchased a new stake in shares of IN8bio in the fourth quarter valued at approximately $43,000. Alyeska Investment Group L.P. boosted its stake in shares of IN8bio by 1,060.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after buying an additional 875,000 shares in the last quarter. HRT Financial LP acquired a new position in IN8bio during the fourth quarter worth $34,000. Finally, Franklin Resources Inc. raised its position in IN8bio by 381.6% in the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after acquiring an additional 724,637 shares in the last quarter. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.